Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc. reported a total net revenue increase of 3.7% year-over-year to $69.4 million, which was supported by the rising volumes of Jeuveau and the successful launch of the Evolysse dermal filler line. The company anticipates a contribution from Evolysse to the 2025 top-line guidance of approximately $33 million, reflecting significant demand strength. Additionally, the overall aesthetic market is projected to expand, particularly among younger consumers who are increasingly favoring aesthetic treatments, which aligns with Evolus's potential for market share growth with its effective product offerings.

Evolus Inc has experienced a decline in its adjusted gross margin, dropping to 66.5% from 71.5% year-over-year, primarily due to an increased focus on international sales and introductory pricing strategies intended to boost adoption. The company has also revised its 2025 net revenue guidance down to $295-$305 million, a significant reduction from the previous estimate of $345-$355 million, indicating a shift from expected 30%-33% growth to only 11%-15%. Additionally, the overall market for aesthetic procedures has contracted, with Jeuveau's sales declining by 11% year-over-year in the most recent quarter—the first drop since its launch—reflecting decreased consumer confidence and market softness.